SARS-CoV-2 disinfection in aqueous solution by UV₂₂₂ from a krypton chlorine excilamp

AUTHORS

- 6 Richard T. Robinson^{1,2}, Najmus Mahfooz¹, Oscar Rosas-Mejia¹, Yijing Liu³, Natalie M.
- 7 Hull^{3,4*}

1

2 3 4

5

8

18

19

22

23

9 **AFFILIATIONS**

- 10 1. Department of Microbial Infection and Immunity, The Ohio State University,
- 11 Columbus, OH, USA
- 12 2. Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA
- 13 3. Department of Civil, Environmental, and Geodetic Engineering, The Ohio State
- 14 University, Columbus, OH, USA
- 15 4. Sustainability Institute, The Ohio State University, Columbus, OH, USA
- 16 * Corresponding author: Natalie Hull, hull.305@osu.edu, 2070 Neil Ave, Hitchcock
- 17 417C, Columbus, OH,43210

KEYWORDS

- 20 COVID-19, SARS-CoV-2, UV Disinfection, ultraviolet light, water treatment, coronavirus,
- 21 qPCR, plaque assay, infectivity, nucleic acid damage, protein damage, ELISA, RNA

ABSTRACT


24

25 There is an urgent need for evidence-based development and implementation of 26 engineering controls to reduce transmission of SARS-CoV-2, the etiological agent of 27 COVID-19. Ultraviolet (UV) light can inactivate coronaviruses, but the practicality of UV 28 light as an engineering control in public spaces is limited by the hazardous nature of 29 conventional UV lamps, which are Mercury (Hg)-based and emit a peak wavelength 30 (254 nm) that penetrates human skin and is carcinogenic. Recent advances in the 31 development and production of Krypton Chlorine (KrCl) excimer lamps hold promise in 32 this regard, as these emit a shorter peak wavelength (222 nm) and are recently being 33 produced to filter out emission above 240 nm. However, the disinfection kinetics of KrCl 34 UV excimer lamps against SARS-CoV-2 are unknown. Here we provide the first dose 35 response report for SARS-CoV-2 exposed to a commercial filtered KrCl excimer light 36 source emitting primarily 222 nm UV light (UV₂₂₂), using multiple assays of SARS-CoV-37 2 viability. Plaque infectivity assays demonstrate the pseudo-first order rate constant of SARS-CoV-2 reduction of infectivity to host cells to be $0.64 \text{ cm}^2/\text{mJ}$ ($R^2 = 0.95$), which 38 39 equates to a D₉₀ (dose for 1 log₁₀ or 90% inactivation) of 1.6 mJ/cm². Through RT-40 qPCR assays targeting the nucleocapsid (N) gene with a short (<100 bp) and long 41 (~1000 bp) amplicon in samples immediately after UV₂₂₂ exposure, the reduction of 42 ability to amplify indicated an approximately 10% contribution of N gene damage to 43 disinfection kinetics. Through ELISA assay targeting the N protein in samples 44 immediately after UV₂₂₂ exposure, we found no dose response of the ability to damage 45 the N protein. In both qPCR assays and the ELISA assay of viral outgrowth 46 supernatants collected 3 days after incubation of untreated and UV222 treated SARS-47 CoV-2, molecular damage rate constants were similar, but lower than disinfection rate 48 constants. These data provide quantitative evidence for UV₂₂₂ doses required to 49 disinfect SARS-CoV-2 in aqueous solution that can be used to develop further 50 understanding of disinfection in air, and to inform decisions about implementing UV₂₂₂ 51 for preventing transmission of COVID19.

ABSTRACT ART / TOC GRAPHIC

53

54 55



INTRODUCTION

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of Coronavirus Disease 2019 (COVID-19), a recently emerged infectious disease with no cure. SARS-CoV-2 spreads primarily from person to person when mucous membranes (e.g., lungs, eyes) are exposed to airborne viruses that have been emitted by infected individuals in particles of various size^{1,2}. Infection leads to a variable disease course affecting multiple organ systems (respiratory, cardiac, neurological and gastrointestinal); for this reason, the symptoms of COVID19 are variable and include asymptomatic infection, fever, cough, dyspnea, malaise, nausea, ageusia/anosmia, delirium and death. A number of antiviral and host-directed therapies have been or are being explored as COVID19 treatments, including low-dose radiation³, nucleoside analogs (e.g. remdesivir⁴, favipiravir⁵), hydroxychloroguine⁶, interferon beta⁷, convalescent plasma^{8,9}, neutralizing monoclonal antibodies^{10,11}, and anti-inflammatories such as dexamethasone¹². IL6 inhibitors¹³, and JAK/STAT inhibitors¹⁴. Prophylactic vaccines against the SARS-CoV-2 Spike protein have also recently become available 15. These treatments and vaccines are causes for optimism during the current COVID19 pandemic, which to date has killed nearly 2 million individuals; however, even after vaccines become widely available, social distancing, face masks and other engineering solutions that limit transmission will continue to be needed in the foreseeable future for this and other emerging infectious diseases¹⁶. Ultraviolet (UV) irradiation is an effective means of inactivating a number of respiratory viruses, including human coronavirus OC43 (HCoV-OC43, a cause of the common cold¹⁷) and SARS-CoV (etiological agent of the 2002 SARS epidemic^{18–20}). UV is commonly applied for upper room air disinfection, in HVAC systems, and in freestanding air and surface purifiers. The feasibility of using UV on a widespread and evidence-based level to minimize transmission of SARS-CoV-2, however, is currently limited by two reasons: (1) conventional mercury-based low pressure UV lamps are impractical in many settings as they are hazardous to human health (the 254 nm wavelength emission causes skin cancer²¹ and cataracts²²) and the environment

(mercury from breaking fragile quartz lamp bulbs is toxic²³), (2) the UV dose response kinetics needed to inactivate SARS-CoV-2 are unknown. Should these two challenges be overcome, the use of UV to inactivate SARS-CoV-2 in environments with high potential for transmission (e.g. congregate care facilities, convalescent patient homes, hospital waiting rooms, airplane cabins) would be a practical and readily deployed engineering solution to augment current prophylactic measures (social distancing, face masks, vaccines). Due to a surge in interest and application of UV in various public settings, there is an urgent need to understand the dose response kinetics of SARS-CoV-2 to UV radiation to inform decisions which balance the risk to eyes and skin from UV exposure with the risk of infection from virus transmission. Here we demonstrate the dose response kinetics of SARS-CoV-2 in liquid after exposure to primarily 222 nm UV light emitted by a krypton-chlorine (KrCl) excimer lamp (excilamp) filtered to reduce transmission of more harmful wavelengths > 240 nm. The lower wavelength emission (222 nm) is neither carcinogenic in human skin models or rodents²⁴, nor causes acute corneal damage in rodents²⁵. Additionally, the 222 nm wavelength emitted by KrCl excilamps is inherently more effective at disinfection²⁶, nucleic acid damage²⁷, and protein damage^{28,29} than 254 nm emitted by low pressure mercury lamps due to greater absorbance of target biomolecules at lower wavelengths. Krypton and chlorine in KrCl excilamps are much less toxic than mercury, and KrCl excilamps have already been shown to be competitive in terms of electrical efficiency with mercury lamps that have many more years of product development and optimization³⁰. Our results demonstrate that when an aqueous solution of pathogenic SARS-CoV-2 is exposed to UV₂₂₂ light emitted by a Kr-Cl excilamp, its infectivity and integrity is attenuated in a UV dose-dependent manner, as measured by culture and molecular assays. These first UV₂₂₂ disinfection dose responses demonstrate the feasibility of UV as an approach to inactivate SARS-CoV-2.

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

METHODS

114

115

SARS-CoV-2 culture

116 SARS-CoV-2, Isolate USA-WA1/2020, was obtained from Biodefense and Emerging 117 Infections Research Resources Repository (BEI Resources, Batch # 70034262) and 118 stored and cultured in the Ohio State University Biosafety Level 3 laboratory (IBC 119 Protocol # 2020R00000046). The viral stock used in this study was established by 120 thawing the Batch, diluting it 1:10,000 into incomplete DMEM (Gibco Cat# 11995-065, 121 supplemented with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate), and adding it to 122 T175 flasks of confluent Vero cells (ATCC clone E6) for a one hour incubation period 123 (37°C, 5% CO₂), after which the supernatant was removed and replaced with complete 124 DMEM (cDMEM; DMEM as above plus 4% heat-inactivated fetal bovine serum). These 125 T175 flasks were incubated for 3 days (37°C, 5% CO₂) to propagate infectious virus. At 126 the end of this period, visual inspection of the flasks under a light microscope 127 demonstrated that the nearly all Vero cells were dead. The supernatants in each of the 128 T175 flasks were presumed to contain infectious virus at this point, were carefully 129 transferred and combined into a 50mL conical, centrifuged at low speed to remove cell 130 debris, aliquoted into microcentrifuge tubes, frozen and stored at -80°C. The live virus 131 titer in frozen aliquots was determined to be ~10⁷ plaque forming unit (PFU) per mL 132 using a modified version of plaque assay developed by the Diamond laboratory³¹ and 133 described below. **UV Dose Calculations** 134 135 The UV₂₂₂ light source (USHIO Care222[®]) is a KrCl excilamp that is optically filtered to 136 reduce emission > 240 nm. The UV source was turned on to warm up for 15 minutes 137 before any irradiance or spectral measurements or irradiations. Standardized 138 procedures were followed for carrying out quasi-collimated beam disinfection studies³² 139 and calculating polychromatic UV doses³³. The emission spectrum of the UV₂₂₂ source 140 was measured using a NIST-traceable calibrated Ocean Optics HDX UV-Vis

spectroradiometer with an extreme solarization resistant 455 µ fiber and Spectralon

diffusing cosine corrector detector. Raw spectral data from the OceanView software was interpolated to integer wavelengths using the FORECAST function in Microsoft Excel and relativized to peak emission at 222 nm for use in dose calculations (Figures 1 and S1). Total incident UV-C irradiance was measured using an International Light Technologies (ILT) 2400 radiometer with a SED 220/U solar blind detector, W Quartz wide eye diffuser for cosine correction, and peak irradiance response NIST-traceable calibration. For irradiance measurement, the peak wavelength calibration value was input manually as the radiometer factor. The incident irradiance was measured with the detection plane of the radiometer centered at the height and location of the sample surface during UV exposures, and corrected for several factors to determine the average irradiance through the sample depth. Spatial nonuniformity of emission was accounted for each test by measuring irradiance at 0.5 cm increments from the center to the edge of the petri dish and relativized to determine a petri factor, which was always > 0.9. The typical detector spectral response was obtained from ILT and used to calculate the radiometer factor integrated over the lamp emission, which was 0.9971. As previously³⁴, the reflection factor for water at the 222 nm peak wavelength was assumed to be 0.9726. The divergence factor was determined each experiment day by accounting for the distance between the lamp and the sample surface, and the sample depth and was always > 0.9. The water factor was determined each sample day by the ratio between the incident irradiance and the average irradiance integrated through the sample depth after wavelength-specific absorption. The UV-vis absorbance of virus working stocks (prepared fresh for each test) was measured in the biosafety cabinet using a NanodropTM One^C spectrophotometer via the microvolume pedestal for wavelengths 200 - 295 nm and the 1 cm quartz cuvette for wavelengths above 195 nm. Working stock absorbance spectra for each test are shown in Figures 1 and S1. After these adjustments to incident irradiance in the center of the sample, the average irradiance was used to calculate exposure times (max: 15 minutes; min: 15 seconds) for pre-determined UV doses (0-40 mJ/cm²) (summarized in Supplementary Table S1).

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168




Figure 1: (A) The raw spectral emission from 200 - 300 nm of the filtered KrCl excilamp (USHIO Care222®) was interpolated and relativized to the peak emission at 222 nm for use in UV dose calculations. (B) The absorbance spectrum from 200 - 300 nm of SARS-CoV-2 at ~10⁵ PFU/mL in cDMEM was measured for each of three biologically independent Tests for use in UV dose calculations. Expanded emission and absorbance spectra from 200 - 800 nm are shown in Supplementary Figure S1.

UV Treatment

All UV measurements, sample preparation, UV treatments, and subsequent handling of treated samples were performed in a biosafety cabinet. On the day of each three biologically independent tests while the UV source warmed up and measurements were taken for dose calculations, aliquots of SARS-CoV-2 (previously tittered at 10⁷ PFU/mL) were diluted in cDMEM to make a "working stock solution" with a target titer of 10⁵ PFU/mL. For each UV dose tested, 3 mL of the working stock solution was pipetted into

a 3.7 cm² area and 3.5 cm diameter polystyrene tissue culture dish (VWR Catalog # 82050-538) with a sterile Teflon-coated micro stir bar (VWR Catalog # 58948-353) and positioned under the UV light on a small stir plate to achieve quiescent mixing while blocking the UV light with a shutter. After removing the tissue culture dish lid, the shutter was removed to expose the sample to UV light for the calculated exposure time corresponding to the pre-determined UV dose before replacing the aperture to end the UV exposure. Immediately afterwards, the treated media was transferred to a sterile 15 mL polypropylene centrifuge tube (VWR) and used for the assays described below. Working stocks for untreated samples were placed on the stir plate for a representative amount of time with the lamp off before transfer to centrifuge tube (0 mJ/cm²).

SARS-CoV-2 plaque assay

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

Plaque assays were used to determine PFU/mL of samples before UV treatment (0 mJ/cm²) and after UV treatment (all other UV doses). The plaque assay used for this study is a modification of that which was originally developed and reported by Case et al,³¹ and is listed here as STEPS 1-5. (**STEP 1**) At least 18 hours prior to the assay, 12well plates were seeded with a sufficient number of Vero cells so that each well was confluent by the assay start; plates were incubated overnight at 37°C. (STEP 2) On the day of the assay, serial dilutions of virus-containing media (e.g UV treated virus samples) were prepared in cDMEM (1:10¹, 1:10², 1:10³, 1:10⁴) and warmed to 37°C. (STEP 3) Media from each well of the 12-well plate was gently removed via pipette and replaced with 500uL of each virus serial dilution, the volume pipetted down the side of the well so as not to disturb the Vero cell monolayer. (STEP 4) The plate was incubated for one hour at 37°C, 5% CO₂. (**STEP 5**) During that infection incubation period, a solution comprising a 1:0.7 mixture of cDMEM and 2% methylcellulose (viscosity: 4000 cP) was freshly made and warmed to 37°C in a water bath. After the one hour infection incubation period, the supernatant was removed from each well and replaced with 1 mL of the warmed cDMEM/methylcellulose mixture. (STEP 6) The culture plate was then returned to the incubator and left undisturbed for 3 days. On the final day, cDMEM/methylcellulose mixture was removed from each well, cells were fixed with 4% para-formaldehyde in PBS (20 minutes, room temperature), washed with PBS and

stained with 0.05% crystal violet (in 20% methanol). After rinsing plates with distilled water, plates were dried and plaques were counted under a light microscope at 20X magnification.

SARS-CoV-2 outgrowth assay

The virus outgrowth assay used for this study is identical to the plaque assay described above, with the exception that after **STEP 4** the virus laden media was replaced with 1 mL of warm cDMEM (instead of a cDMEM/methylcellulose mixture). Afterwards, the culture plate was returned to the incubator and left undisturbed for 3 days. On the final day, the cell supernatants of each well were collected, transferred into a microcentrifuge tube, centrifuged at low speed to remove cell debris (1,000 x g, 10 min), aliquoted into microcentrifuge tubes, frozen and stored at -80°C. Aliquots were subsequently used for quantitative real time PCR (qRT-PCR) measurement of SARS-CoV-2 nucleocapsid (N) gene copies, as well as ELISA determination of SARS-CoV-2 N protein concentrations.

SARS-CoV-2 N gene quantitation - N1 primer set

Quantitative PCR (qPCR) was used to quantify the SARS-CoV-2 N gene directly in RNA extracts of samples before UV treatment (0 mJ/cm²) and after UV treatment (all other UV doses), and in RNA extracts of cell supernatant aliquots from outgrowth assays. RNA was extracted from samples using the QIAamp Viral RNA method (Qiagen), and converted to cDNA using the SuperScript IV first strand synthesis method with random hexamer primers (Invitrogen). cDNA was subsequently amplified with the "N1 primer set" and associated PCR conditions that were originally developed by the Centers for Disease Control³⁵. These primers are specific to nucleotides 13-85 of the N gene (NCBI Ref Seq NC_045512.2) and generate a short (72 nt) amplicon: 2019-nCoV_N1-F (forward) primer, 5'-GACCCCAAAATCAGCGAAAT-3'; 2019-nCoV_N1-R (reverse) primer, 5'-TCTGGTTACTGCCAGTTGAATCTG-3'. cDNA was PCR-amplified in a quantitative PCR (q-PCR) assay comprising 1X TaqMan Universal PCR Master Mix (Applied Biosystems), the N1 forward/reverse primers described above (final concentration: 500 nM) and a fluorophore-conjugated N1 TaqMan probe (5'-FAM-

ACCCCGCATTACGTTTGGTGGACC-BHQ1-3'; final concentration 125 nM), q-PCR assays were run on a BioRad CFX Connect Real Time PCR system to determine CT values from samples and standards. A standard curve was generated for the N1 primer set by running serial dilutions on each plate of in vitro transcribed RNA converted to cDNA relating N gene copy numbers to C_T values. To generate this standard, RNA was extracted from an aliquot of our SARS-CoV-2 stock and converted to cDNA before amplification of the N gene using the N1 primer set as described above. The amplicon was visualized by agarose gel electrophoresis, gel extracted and cloned/ligated into the plasmid vector pCR II-TOPO (Invitrogen), downstream of the T7 promoter. Ligation products were transformed into E. coli, and mini-preps of randomly selected colonies were screened via PCR for the presence of insert. A single clone was then used to produce in vitro transcribed (IVT) N gene RNA—a reagent necessary for accurate gene copy number measurement—using the HiScribe T7 Quick High Yield RNA Synthesis method (New England Biolabs). After treating the IVT RNA with DNase and performing a cleanup reaction, the RNA concentration was determined via Nanodrop. The copies of single stranded N gene RNA transcripts per µL was determined by the following equation: [RNA concentration (Nanodrop measurement, ng/µL) x the Avogadro number (6.02 x 10²³)] / [Predicted molecular weight of transcript (23 kDa) x 10⁹]. Serial dilutions of IVT RNA were made (range: $10^{13} \rightarrow 10^{-1}$ copies/ μ L), converted to cDNA as above and used as standards in the N gene copy number assay described above.

SARS-CoV-2 N gene quantitation - N1-2 primer set

qPCR was used to quantify the SARS-CoV-2 N gene in RNA extracts of samples of working stocks before UV treatment (0 mJ/cm²) and immediately after UV treatment (all other UV doses). RNA was extracted from samples and converted to cDNA as described above. cDNA was subsequently quantified using a combination of the CDC 2019 N1 and N2 primer sets to generate a long (944 nt) amplicon: 2019-nCoV_N1-F (forward) primer, 5'-GACCCCAAAATCAGCGAAAT-3'; 2019-nCoV_N2-R (reverse) primer, 5'-GCGCGACATTCCGAAGAA-3'. Primers were obtained from IDT and final concentrations were 500 nM, in 10 μL SsoFast EvaGreen Supermix (BIO-RAD) and 7.75 μL nuclease free water (Fisher Scientific) and 2 μL cDNA template. Reactions with

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

total volume of 20 µL were run in at least technical duplicate on an Applied Biosystems QuantStudio 7 Real-Time PCR system to determine C_T values from samples and standards. For the N1-2 primer set, the standard consisted of serial dilutions of the double stranded DNA control plasmid of the complete N gene (2019-nCoV_N_Positive Control, IDT). **SARS-CoV-2 N protein ELISA** The concentration of N protein in outgrowth assay supernatants was determined using the SARS-CoV-2 Antigen Quantitative Assay Kit (ELISA) method (ADS Biotec). Manufacturer-provided calibration controls were used to establish a standard curve related N protein concentration to sample absorbance (wavelength: 450 nm). Values outside the standard curve were diluted further and rerun as appropriate. The positive signal for SARS-CoV-2 was 2.7 x 10⁵ + 9.8 x 10⁴ pg/mL in untreated virus samples at Day 0 and $1.4 \times 10^8 + 3.0 \times 10^8$ pg/mL in cell culture supernatants incubated with untreated virus samples at Day 3. No N protein was detected in negative control cell culture supernatants that were incubated without virus samples. **Graphing and Statistics** Graphs were prepared using either GraphPad Prism or Microsoft Excel programs; statistical analyses (including regression using the data analysis add-in to determine standard error of regression coefficients) were performed using these programs' bundled software. Log₁₀ Reduction (LR) was calculated as log₁₀(N₀/N), where N was viral PFU/mL in the plaque assay, N gene copies/µL in qPCR assays for either the short N1 amplicon or the long N1-2 amplicon, or N protein concentration in pg//mL in the ELISA assay after exposure to a given UV₂₂₂ dose, and N₀ was the initial concentration. The level of replication in this study was three biologically independent tests, with at least technical duplicates for each assay.

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

RESULTS

SARS-CoV-2 Infectivity Response to UV₂₂₂

Viral infectivity UV₂₂₂ dose response was characterized by exponential decay kinetics (Figure 2). At a mean initial viral titer of $6.51x10^4$ PFU/mL, the pseudo first order rate constant for viral disinfection was -1.48 cm²/mJ (R² = 0.89). When expressed as LR of viral infectivity after exposure to a given UV dose, the linear rate constant was 0.64 cm²/mJ (R² = 0.95), which equates to a D₉₀ (dose for 1 log₁₀ or 90% inactivation) = 1.6 mJ/cm². Doses ranges and initial Vero cell confluence were only sufficient in the Test 3 experimental replicate to quantify a dose response. However, in Test 2, the mean initial viral titer of $3.54x10^4$ PFU/mL in untreated samples was reduced to below detection by the first dose tested of 10 mJ/cm², equivalent to a LR of at least 4.25 logs. These results were also consistent with qualitative results from Test 1, where Vero cells appeared mostly dead in the untreated samples, appeared increasingly healthy through doses 0.7 and 1.4 mJ/cm², and appeared healthy at doses above 2 mJ/cm².




Figure 2: (A) SARS-CoV-2 titers measured by plaque assay 3 days after sample exposure to each UV₂₂₂ dose (dark circles) were fit with an exponential model starting at the mean initial (0 mJ/cm²) viral titer of 6.51x10⁴ PFU/mL through responses up to and including 8 mJ/cm² where PFU/mL first dropped below the assay detection limit (DL) of 2 PFU/mL (hollow circles). Error bars represent standard deviation of at least two technical replicates. (B) SARS-CoV-2 log₁₀ reductions (LR) of viral titers after exposure to each UV₂₂₂ dose (dark circles) were fit with a linear model forced through the origin at 0 mJ/cm² through responses up to and including 8 mJ/cm² where LR first exceeded the DL of 4.51 logs (hollow circles).

SARS-CoV-2 N Gene and Protein Response to UV₂₂₂

For the short amplicon spanning the N1 region of the N gene (CDC 2019), viral RNA damage in response to UV₂₂₂ immediately after treatment was also characterized by

exponential decay kinetics (Figure 3A). When expressed as LR of N1 copies/µL in qPCR reactions after exposure to a given UV dose, the linear rate constant was 0.069 + $0.005 \text{ cm}^2/\text{mJ}$ (slope + standard error, $R^2 = 0.92$). The N1 dose response was modeled using the linear region between 0 - 20 mJ/cm² to avoid tailing in the dose response. When including only doses up to 10mJ/cm² as for the plaque assay, the slope and R² of the N1 gene damage dose response was the same as for doses up to 20 mJ/cm². Compared with the LR rate constant for of SARS-CoV-2 infectivity measured by plaque assay, the LR rate constant of N gene damage measured by N1 qPCR was approximately 10-fold lower. Across all tests, the positive signal for SARS-CoV-2 in the N1 assay was 10.75 + 0.25 log₁₀ copies/μL in cell cultures infected with untreated virus (0 mJ/cm²), 4.89 + 0.86 log₁₀ copies/μL in uninfected cell culture supernatants, 5.49 log₁₀ copies/μL in RNA extraction negative control, 3.36 + 0.24 log₁₀ copies/μL in no template RT-qPCR reaction controls (concentration data and standard curves shown in Supplementary Figures S2 and S3). Despite this background signal, dose responses were still discernable. For the N1 dose response after 3 days in the outgrowth assay for doses up to 0 - 20 mJ/cm², the linear rate constant was 0.260 ± 0.036 cm²/mJ (slope ± standard error, $R^2 = 0.76$). Although a positive dose response was apparent and the slope was closer to the plague assay (indicating better ability to predict plague assay dose response with combined cell culture with qPCR), the increased variability introduced by cell culture decreased the strength of the regression. For the long amplicon spanning both the N1 and N2 regions of N gene (CDC 2019), viral RNA damage in response to UV₂₂₂ immediately after treatment was also characterized by exponential decay (Figure 3B). The linear rate constant for LR versus UV_{222} dose was 0.054 + 0.003 cm²/mJ (slope + standard error, $R^2 = 0.94$). Compared with the LR rate constant for of SARS-CoV-2 infectivity measured by plaque assay, the LR rate constant of N gene damage measured by N1-2 qPCR was approximately 10fold lower. This similarity indicates that increasing the amplicon length did not increase the ability to detect gene damage that correlates with loss of viral infectivity. Across all tests, the positive signal for SARS-CoV-2 in the N1-2 assay was 4.6 + 0.1 log₁₀ copies/uL in cell cultures infected with untreated virus, undetected in uninfected cell

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

culture supernatants, and 0.8 + 1.4 copies/μL in no template RT-qPCR reaction controls (concentration data and standard curves shown in Supplementary Figures S2 and S3). Because the long amplicon assay was used to investigate potential for improved measurement of disinfection dose response without culture, no Day 3 samples were analyzed. Although no dose response was observed for LR of the N protein versus UV222 dose immediately after treatment for doses up to 40 mJ/cm² (0.002 + 0.001 cm²/mJ, slope + standard error, $R^2 = 0.21$), a stronger dose response was observed in Day 3 cell culture supernatants for doses up to 20 mJ/cm² (0.243 + 0.028 cm²/mJ, slope + standard error, R² = 0.21) (Figure 3C). Across all tests, the positive signal for SARS-CoV-2 in the N protein assay was 2.69x10⁵ + 9.83x10⁴ pg/mL in untreated virus samples on Day 0, 1.41x10⁸ + 2.99x10⁸ in Day 3 cell culture supernatants infected with untreated virus, and below detection in uninfected cell culture supernatants (concentration data and standard curves shown in Supplementary Figures S2 and S3). Gene copies/µL for both qPCR assays and protein pg/mL for the ELISA assay are shown for each UV₂₂₂ dose in Supplementary Figure S2 and standard curves for all assays are shown in Supplementary Figure S3.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377




Figure 3: (A) SARS-CoV-2 N gene damage immediately after UV treatment (Day 0) and after incubation of samples with host cells (Day 3) expressed as log₁₀ reduction of N1 (short amplicon) copies/μL in qPCR reactions. (B) SARS-CoV-2 N gene damage immediately after UV treatment (Day 0) expressed as log₁₀ reduction of N1-2 (long amplicon) copies/μL in qPCR reactions. (C) SARS-CoV-2 N protein concentration measured by ELISA expressed as log₁₀ reduction of N protein concentration (pg/mL) in samples immediately after UV treatment (Day 0) and after incubation of samples with host cells (Day 3). SARS-CoV-2 log₁₀ reductions of the N1 amplicon, N1-2 amplicon, or

N protein versus UV₂₂₂ dose were fit with a linear model forced through the origin at 0 mJ/cm² through responses up to and including 20 mJ/cm² indicated by filled circles. Points not included in models are indicated by hollow circles. DISCUSSION This study provides the first rigorous UV₂₂₂ dose response kinetics for SARS-CoV-2 in aqueous solution, but there are limitations that must be acknowledged. Most importantly, this study was conducted using virions suspended in aqueous solution. This is only a starting point for quantifying dose response kinetics for airborne virus disinfection that is most relevant for this virus, where many factors such as temperature, humidity, air flow dynamics, and UV reactor specifics will impact dose responses. Previous studies comparing disinfection kinetics of infectious agents in air at increasing relative humidity to those in water^{36–41} indicate that these water dose responses may present a conservative estimate of airborne disinfection kinetics because humidity in many indoor environments is conditioned to reduce infectious agent persistence One additional limitation of this study related to UV₂₂₂ application in indoor environments is that the disinfection impact of any ozone production by vacuum UV wavelengths potentially emitted by the KrCl excilamp was not measured, but can likely be neglected due to high airflows in the biosafety cabinet and BSL3 facility. The negative air quality impacts and building material degradation by ozone potentially generated by these lamps, and the potential health hazards and building material solarization from wavelengths below 240 nm and the nonzero emission at wavelengths above 240 nm (Supplementary Figure S1), should also be considered when weighing the benefits of reducing infectious disease transmission by UV₂₂₂ for COVID-19 and other infectious diseases. Considering these limitations, these data provide a strong foundation for future development and application of UV₂₂₂ for reducing airborne viral transmission. UV₂₂₂ is both 4.2 times safer for human exposure (the threshold limit values for human UV

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

exposure are 25 mJ/cm² and 6 mJ/cm² at 222 and 254 nm, respectively⁴¹) and at least 1.3 times as effective at disinfecting SARS-CoV-2 (the D₉₀ we observed for UV₂₂₂ (1.6 mJ/cm²) is lower than recently predicted by genomic modeling for UV₂₅₄ (2.15 mJ/cm²)⁴²). A recent study applying continuous UV₂₂₂ at doses below these threshold limit values to treat other airborne coronaviruses demonstrated multiple logs of inactivation within minutes⁴³. This low wavelength advantage for SARS-CoV-2 disinfection is consistent with a study where UV₂₂₂ was more than twice as effective as UV₂₅₄ against MS2 bacteriophage³⁴ and with other viral action spectra indicating greater sensitivity at 222 nm than 254 nm²⁶. A recent review⁴⁴ predicted the median D₉₀ for coronavirus disinfection by UV₂₅₄ to be 3.7 mJ/cm². Our results and these predictions are in general agreement with recent UV222 and UV254 disinfection studies of SARS-CoV-2 as recently reviewed⁴¹. However, some of these studies are still in the process of peer review and/or did not use standardized UV disinfection procedures that allow comparisons between experiments and precise quantification of doses. In the only UV₂₂₂ SARS-CoV-2 surface decontamination study to date ⁴⁵, researchers report 0.94 LR after 10 second exposure to 0.1 mW/cm². Although UV dose cannot be calculated for this study in the absence of sample absorbance and differences in experimental setup, these results demonstrate a high degree of susceptibility of SARS-CoV-2 to UV₂₂₂ and generally align with ours. Considering our data in context of literature, UV₂₂₂ is a promising disinfection method for SARS-CoV-2 in aqueous solution. These infectivity and molecular dose response data could immediately inform measures to prevent transmission by water or wastewater where infectious SARS-CoV-2 and other viruses have been shown to be potentially persistent for days^{46,47}. Although tailing was observed in dose responses for molecular assays and may have been contributed from clumping of virus in the protein-laden growth media, viruses were disinfected below detection in plaque assays, indicating that aggregation did not interfere with complete viral inactivation. We did not observe a strong relationship between the kinetics of N gene damage (measured by gPCR with a short and long amplicon) and disinfection, which could reflect that protein damage contributes more to disinfection than genome damage for SARS-CoV-2. One study of

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

MS2 bacteriophage found RNA genome damage to be closely related to and thus contributed to disinfection kinetics²⁷, whereas a study of Adenovirus found DNA genome damage not to be closely related to disinfection⁴⁸. This disparity between these viruses with different structures and hosts was further demonstrated when it was shown that protein damage, especially to external capsid proteins, contributes more strongly to UV disinfection of Adenovirus⁴⁹. However, we also did not see a strong association between the kinetics of N protein damage and disinfection. Because we only measured the N protein that closely associates with the viral genome, we may have missed damage to external proteins such as the spike protein which are on the surface to absorb incoming UV radiation and are vital in infection of host cells⁵⁰. Additionally, the confirmation and sequence of the genome and proteins can affect UV genetic damage^{51–55}, so the N protein and gene may not be the targets that primarily contribute to disinfection-inducing molecular damage. These factors could explain the weak relationships we observed between disinfection kinetics and N gene damage or N protein damage, and warrant further investigation to unravel the mechanisms of disinfection at this and other UV wavelengths. While these mechanistic complexities remain to be resolved, the disinfection kinetics we report indicate the high degree of susceptibility of SARS-CoV-2 in aqueous solution to UV₂₂₂.

ACKNOWLEDGEMENTS

This work was supported by funds from The Ohio State University (OSU) Sustainability Institute; OSU Infectious Disease Institute; OSU Department of Civil, Environmental, and Geodetic Engineering (Chair: Dr. Allison MacKay); OSU Department of Microbial Infection & Immunity (Chair: Dr. Eugene Oltz); and National Institutes of Health (U54 CA260582). Anna Herman of AquiSense Technologies shared a list of references to SARS-CoV-2 UV disinfection studies. The UV₂₂₂ light source (USHIO Care222®) was provided by USHIO, Inc. through material transfer agreement 2020-2654 to Hull at OSU.

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

REFERENCES

- 483 (1) Samet, J. M.; Prather, K.; Benjamin, G.; Lakdawala, S.; Lowe, J.-M.; Reingold, A.;
- Volckens, J.; Marr, L. Airborne Transmission of SARS-CoV-2: What We Know.
- 485 *Clin. Infect. Dis.* **2021**. https://doi.org/10.1093/cid/ciab039.
- 486 (2) Tang, J. W.; Bahnfleth, W. P.; Bluyssen, P. M.; Buonanno, G.; Jimenez, J. L.;
- Kurnitski, J.; Li, Y.; Miller, S.; Sekhar, C.; Morawska, L.; et al. Dismantling Myths
- on the Airborne Transmission of Severe Acute Respiratory Syndrome
- 489 Coronavirus (SARS-CoV-2). J. Hosp. Infect. 2021.
- 490 https://doi.org/10.1016/j.jhin.2020.12.022.
- 491 (3) Hess, C. B.; Buchwald, Z. S.; Stokes, W.; Nasti, T. H.; Switchenko, J. M.;
- Weinberg, B. D.; Steinberg, J. P.; Godette, K. D.; Murphy, D.; Ahmed, R.; et al.
- 493 Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day 7
- Interim Analysis of a Registered Clinical Trial. *Cancer* **2020**, *126* (23), 5109–5113.
- 495 https://doi.org/10.1002/cncr.33130.
- 496 (4) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.;
- 497 Lu, Q.; et al. Remdesivir in Adults with Severe COVID-19: A Randomised,
- 498 Double-Blind, Placebo-Controlled, Multicentre Trial. *Lancet* **2020**, 395 (10236),
- 499 1569–1578. https://doi.org/10.1016/S0140-6736(20)31022-9.
- 500 (5) Ison, M. G.; Scheetz, M. H. Understanding the Pharmacokinetics of Favipiravir:
- 501 Implications for Treatment of Influenza and COVID-19. *EBioMedicine*. Elsevier
- 502 B.V. January 1, 2021. https://doi.org/10.1016/j.ebiom.2020.103204.
- 503 (6) Cavalcanti, A. B.; Zampieri, F. G.; Rosa, R. G.; Azevedo, L. C. P.; Veiga, V. C.;
- Avezum, A.; Damiani, L. P.; Marcadenti, A.; Kawano-Dourado, L.; Lisboa, T.; et
- al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
- 506 N. Engl. J. Med. **2020**, 383 (21), 2041–2052.
- 507 https://doi.org/10.1056/nejmoa2019014.
- 508 (7) Monk, P. D.; Marsden, R. J.; Tear, V. J.; Brookes, J.; Batten, T. N.; Mankowski,
- M.; Gabbay, F. J.; Davies, D. E.; Holgate, S. T.; Ho, L. P.; et al. Safety and
- 510 Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of
- 511 SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase

- 512 2 Trial. Lancet Respir. Med. **2020**. https://doi.org/10.1016/S2213-2600(20)30511-
- 513 7.
- 514 (8) Simonovich, V. A.; Burgos Pratx, L. D.; Scibona, P.; Beruto, M. V.; Vallone, M. G.;
- Vázguez, C.; Savoy, N.; Giunta, D. H.; Pérez, L. G.; Sánchez, M. del L.; et al. A
- 516 Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N.*
- 517 Engl. J. Med. **2020**. https://doi.org/10.1056/nejmoa2031304.
- 518 (9) Joyner, M. J.; Carter, R. E.; Senefeld, J. W.; Klassen, S. A.; Mills, J. R.; Johnson,
- P. W.; Theel, E. S.; Wiggins, C. C.; Bruno, K. A.; Klompas, A. M.; et al.
- 520 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N.*
- 521 Engl. J. Med. **2021**. https://doi.org/10.1056/nejmoa2031893.
- 522 (10) Weinreich, D. M.; Sivapalasingam, S.; Norton, T.; Ali, S.; Gao, H.; Bhore, R.;
- Musser, B. J.; Soo, Y.; Rofail, D.; Im, J.; et al. REGN-COV2, a Neutralizing
- Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. 2020, 384 (3).
- 525 https://doi.org/10.1056/nejmoa2035002.
- 526 (11) Chen, P.; Nirula, A.; Heller, B.; Gottlieb, R. L.; Boscia, J.; Morris, J.; Huhn, G.;
- 527 Cardona, J.; Mocherla, B.; Stosor, V.; et al. SARS-CoV-2 Neutralizing Antibody
- 528 LY-CoV555 in Outpatients with Covid-19. *N. Engl. J. Med.* **2020**, *384* (3).
- 529 https://doi.org/10.1056/nejmoa2029849.
- 530 (12) Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. N.
- 531 Engl. J. Med. **2020**. https://doi.org/10.1056/nejmoa2021436.
- 532 (13) Stone, J. H.; Frigault, M. J.; Serling-Boyd, N. J.; Fernandes, A. D.; Harvey, L.;
- Foulkes, A. S.; Horick, N. K.; Healy, B. C.; Shah, R.; Bensaci, A. M.; et al. Efficacy
- of Tocilizumab in Patients Hospitalized with Covid-19. *N. Engl. J. Med.* **2020**, 383
- 535 (24), 2333–2344. https://doi.org/10.1056/nejmoa2028836.
- 536 (14) Cao, Y.; Wei, J.; Zou, L.; Jiang, T.; Wang, G.; Chen, L.; Huang, L.; Meng, F.;
- Huang, L.; Wang, N.; et al. Ruxolitinib in Treatment of Severe Coronavirus
- 538 Disease 2019 (COVID-19): A Multicenter, Single-Blind, Randomized Controlled
- 539 Trial. J. Allergy Clin. Immunol. **2020**, 146 (1), 137-146.e3.
- 540 https://doi.org/10.1016/j.jaci.2020.05.019.
- 541 (15) Polack, F. P.; Thomas, S. J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.;
- Perez, J. L.; Pérez Marc, G.; Moreira, E. D.; Zerbini, C.; et al. Safety and Efficacy

- of the BNT162b2 MRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383 (27),
- 544 2603–2615. https://doi.org/10.1056/nejmoa2034577.
- 545 (16) Goel, S.; Hawi, S.; Goel, G.; Thakur, V. K.; Agrawal, A.; Hoskins, C.; Pearce, O.;
- Hussain, T.; Upadhyaya, H. M.; Cross, G.; et al. Resilient and Agile Engineering
- 547 Solutions to Address Societal Challenges Such as Coronavirus Pandemic. *Mater.*
- 548 Today Chem. **2020**, 17. https://doi.org/10.1016/j.mtchem.2020.100300.
- 549 (17) Gerchman, Y.; Mamane, H.; Friedman, N.; Mandelboim, M. UV-LED Disinfection
- of Coronavirus: Wavelength Effect. J. Photochem. Photobiol. B Biol. 2020, 212.
- 551 https://doi.org/10.1016/j.jphotobiol.2020.112044.
- 552 (18) Kariwa, H.; Fujii, N.; Takashima, I. Inactivation of SARS Coronavirus by Means of
- Povidone-Iodine, Physical Conditions and Chemical Reagents. *Dermatology*
- **2006**, *212* (SUPPL. 1), 119–123. https://doi.org/10.1159/000089211.
- 555 (19) Darnell, M. E. R.; Subbarao, K.; Feinstone, S. M.; Taylor, D. R. Inactivation of the
- 556 Coronavirus That Induces Severe Acute Respiratory Syndrome, SARS-CoV. J.
- 557 *Virol. Methods* **2004**, 121 (1), 85–91.
- 558 https://doi.org/10.1016/j.jviromet.2004.06.006.
- 559 (20) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W.
- 560 Stability and Inactivation of SARS Coronavirus. *Med. Microbiol. Immunol.* **2005**.
- 561 194 (1–2), 1–6. https://doi.org/10.1007/s00430-004-0219-0.
- 562 (21) Pfeifer, G. P.; Besaratinia, A. UV Wavelength-Dependent DNA Damage and
- Human Non-Melanoma and Melanoma Skin Cancer. *Photochemical and*
- 564 Photobiological Sciences. Royal Society of Chemistry 2012, pp 90–97.
- 565 https://doi.org/10.1039/c1pp05144j.
- 566 (22) Jose, J. G.; Pitts, D. G. Wavelength Dependency of Cataracts in Albino Mice
- 567 Following Chronic Exposure. *Exp. Eye Res.* **1985**, *41* (4), 545–563.
- 568 https://doi.org/10.1016/S0014-4835(85)80011-7.
- 569 (23) Bjørklund, G.; Dadar, M.; Mutter, J.; Aaseth, J. The Toxicology of Mercury:
- 570 Current Research and Emerging Trends. *Environmental Research*. Academic
- 571 Press Inc. 2017, pp 545–554. https://doi.org/10.1016/j.envres.2017.08.051.
- 572 (24) Buonanno, M.; Ponnaiya, B.; Welch, D.; Stanislauskas, M.; Randers-Pehrson, G.;
- 573 Smilenov, L.; Lowy, F. D.; Owens, D. M.; Brenner, D. J. Germicidal Efficacy and

- 574 Mammalian Skin Safety of 222-Nm UV Light. Radiat. Res. 2017, 187 (4), 483-
- 575 491. https://doi.org/10.1667/RR0010CC.1.
- 576 (25) Kaidzu, S.; Sugihara, K.; Sasaki, M.; Nishiaki, A.; Igarashi, T.; Tanito, M.
- 577 Evaluation of Acute Corneal Damage Induced by 222-Nm and 254-Nm Ultraviolet
- 578 Light in Sprague–Dawley Rats. Free Radic. Res. 2019, 53 (6), 611–617.
- 579 https://doi.org/10.1080/10715762.2019.1603378.
- 580 (26) Beck, S. E.; Wright, H. B.; Hargy, T. M.; Larason, T. C.; Linden, K. G. Action
- Spectra for Validation of Pathogen Disinfection in Medium-Pressure Ultraviolet
- 582 (UV) Systems. Water Res. 2015, 70, 27–37.
- 583 https://doi.org/10.1016/j.watres.2014.11.028.
- 584 (27) Beck, S. E.; Rodriguez, R. A.; Hawkins, M. A.; Hargy, T. M.; Larason, T. C.;
- Linden, K. G. Comparison of UV-Induced Inactivation and RNA Damage in MS2
- 586 Phage across the Germicidal UV Spectrum. *Appl. Environ. Microbiol.* **2016**, 82
- 587 (5), 1468–1474. https://doi.org/10.1128/AEM.02773-15.
- 588 (28) Beck, S. E.; Hull, N. M.; Poepping, C.; Linden, K. G. Wavelength-Dependent
- Damage to Adenoviral Proteins Across the Germicidal UV Spectrum. *Environ. Sci.*
- 590 *Technol.* **2018**. https://doi.org/10.1021/acs.est.7b04602.
- 591 (29) Eischeid, A. C.; Linden, K. G. Molecular Indications of Protein Damage in
- Adenoviruses after UV Disinfection. Appl. Environ. Microbiol. 2011, 77 (3), 1145–
- 593 1147. https://doi.org/10.1128/AEM.00403-10.
- 594 (30) Hull, N. M.; Linden, K. G. Synergy of MS2 Disinfection by Sequential Exposure to
- Tailored UV Wavelengths. Water Res. 2018.
- 596 https://doi.org/10.1016/j.watres.2018.06.017.
- 597 (31) Case, J. B.; Bailey, A. L.; Kim, A. S.; Chen, R. E.; Diamond, M. S. Growth,
- 598 Detection, Quantification, and Inactivation of SARS-CoV-2. *Virology* **2020**, *548*,
- 599 39–48. https://doi.org/10.1016/j.virol.2020.05.015.
- 600 (32) Bolton, J. R.; Linden, K. G. Standardization of Methods for Fluence (UV Dose)
- Determination in Bench-Scale UV Experiments. J. Environ. Eng. 2003, 129 (3),
- 602 209–215. https://doi.org/10.1061/(asce)0733-9372(2003)129:3(209).
- 603 (33) Linden, K. G.; Darby, J. L. Estimating Effective Germicidal Dose from Medium
- 604 Pressure UV Lamps. *J. Environ. Eng.* **1997**, *1*23 (11), 1142–1149.

- 605 https://doi.org/10.1061/(asce)0733-9372(1997)123:11(1142).
- 606 (34) Hull, N. M.; Linden, K. G. Synergy of MS2 Disinfection by Sequential Exposure to
- Tailored UV Wavelengths. Water Res. 2018.
- 608 https://doi.org/10.1016/j.watres.2018.06.017.
- 609 (35) CDC. Real-time RT-PCR Primers and Probes for COVID-19 | CDC
- 610 https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html
- 611 (accessed Feb 4, 2021).
- 612 (36) Peccia, J.; Hernandez, M. UV-Induced Inactivation Rates for Airborne
- 613 Mycobacterium Bovis BCG. J. Occup. Environ. Hyg. **2004**, 1 (7), 430–435.
- 614 https://doi.org/10.1080/15459620490458495.
- 615 (37) Walker, C. M.; Ko, G. Effect of Ultraviolet Germicidal Irradiation on Viral Aerosols.
- 616 Environ. Sci. Technol. **2007**, 41 (15), 5460–5465.
- 617 https://doi.org/10.1021/es070056u.
- 618 (38) Jordan, P.; Werth, H. M.; Shelly, M.; Mark, H. Effects of Relative Humidity on the
- Ultraviolet Induced Inactivation of Airborne Bacteria. Aerosol Sci. Technol. 2001,
- 620 35 (3), 728–740. https://doi.org/10.1080/02786820152546770.
- 621 (39) Kowalski, W. Ultraviolet Germicidal Irradiation Handbook: UVGI for Air and
- *Surface Disinfection*; Springer Berlin Heidelberg, 2009.
- 623 https://doi.org/10.1007/978-3-642-01999-9.
- 624 (40) Tseng, C.-C.; Li, C.-S. Inactivation of Virus-Containing Aerosols by Ultraviolet
- 625 Germicidal Irradiation. *Aerosol Sci. Technol.* **2005**, 39 (12), 1136–1142.
- 626 https://doi.org/10.1080/02786820500428575.
- 627 (41) Raeiszadeh, M.; Adeli, B. A Critical Review on Ultraviolet Disinfection Systems
- against COVID-19 Outbreak: Applicability, Validation, and Safety Considerations.
- 629 **2020**. https://doi.org/10.1021/acsphotonics.0c01245.
- 630 (42) Pendyala, B.; Patras, A.; Pokharel, B.; D'Souza, D. Genomic Modeling as an
- Approach to Identify Surrogates for Use in Experimental Validation of SARS-CoV-
- 2 and HuNoV Inactivation by UV-C Treatment. Front. Microbiol. 2020, 11, 2406.
- 633 https://doi.org/10.3389/fmicb.2020.572331.
- 634 (43) Buonanno, M.; Welch, D.; Shuryak, I.; Brenner, D. J. Far-UVC Light (222 Nm)
- 635 Efficiently and Safely Inactivates Airborne Human Coronaviruses. Sci. Rep. 2020,

- 636 10 (1). https://doi.org/10.1038/s41598-020-67211-2.
- 637 (44) Heßling, M.; Hönes, K.; Vatter, P.; Lingenfelder, C. Ultraviolet Irradiation Doses
- for Coronavirus Inactivation Review and Analysis of Coronavirus
- Photoinactivation Studies. *GMS Hyg. Infect. Control* **2020**, *15*, Doc08.
- 640 https://doi.org/10.3205/dgkh000343.
- 641 (45) Kitagawa, H.; Nomura, T.; Nazmul, T.; Omori, K.; Shigemoto, N.; Sakaguchi, T.;
- Ohge, H. Effectiveness of 222-Nm Ultraviolet Light on Disinfecting SARS-CoV-2
- Surface Contamination. Am. J. Infect. Control 2020, 0 (0).
- https://doi.org/10.1016/j.ajic.2020.08.022.
- 645 (46) Bivins, A.; Greaves, J.; Fischer, R.; Yinda, K. C.; Ahmed, W.; Kitajima, M.;
- Munster, V. J.; Bibby, K. Persistence of SARS-CoV-2 in Water and Wastewater.
- 647 Environ. Sci. Technol. Lett. **2020**, 7 (12), 937–942.
- https://doi.org/10.1021/acs.estlett.0c00730.
- 649 (47) Ye, Y.; Ellenberg, R. M.; Graham, K. E.; Wigginton, K. R. Survivability,
- Partitioning, and Recovery of Enveloped Viruses in Untreated Municipal
- 651 Wastewater. *Environ. Sci. Technol.* **2016**, *50* (10), 5077–5085.
- https://doi.org/10.1021/acs.est.6b00876.
- 653 (48) Rodríguez, R. A.; Bounty, S.; Linden, K. G. Long-Range Quantitative PCR for
- Determining Inactivation of Adenovirus 2 by Ultraviolet Light. *J. Appl. Microbiol.*
- 655 **2013**, 114 (6), 1854–1865. https://doi.org/10.1111/jam.12169.
- 656 (49) Beck, S. E.; Hull, N. M.; Poepping, C.; Linden, K. G. Wavelength-Dependent
- Damage to Adenoviral Proteins Across the Germicidal UV Spectrum. *Environ. Sci.*
- 658 Technol. **2018**, 52 (1), 223–229. https://doi.org/10.1021/acs.est.7b04602.
- 659 (50) Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell Entry
- 660 Mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117* (21).
- https://doi.org/10.1073/pnas.2003138117.
- 662 (51) Rockey, N.; Young, S.; Kohn, T.; Pecson, B.; Wobus, C. E.; Raskin, L.; Wigginton,
- K. R. UV Disinfection of Human Norovirus: Evaluating Infectivity Using a Genome-
- Wide PCR-Based Approach. *Environ. Sci. Technol.* **2020**, *54* (5), 2851–2858.
- https://doi.org/10.1021/acs.est.9b05747.
- 666 (52) Ye, Y.; Chang, P. H.; Hartert, J.; Wigginton, K. R. Reactivity of Enveloped Virus

667 Genome, Proteins, and Lipids with Free Chlorine and UV254. Environ. Sci. 668 Technol. 2018, 52 (14), 7698–7708. https://doi.org/10.1021/acs.est.8b00824. 669 (53)Wigginton, K. R.; Menin, L.; Sigstam, T.; Gannon, G.; Cascella, M.; Hisham, J; 670 Hamidane, B.; Tsybin, Y. O.; Waridel, P.; Kohn, T. UV Radiation Induces 671 Genome-Mediated, Site-Specific Cleavage in Viral Proteins. ChemBioChem 2012, 672 13, 837-845. https://doi.org/10.1002/cbic.201100601. 673 (54)Wigginton, K. R.; Kohn, T. Virus Disinfection Mechanisms: The Role of Virus 674 Composition, Structure, and Function. Current Opinion in Virology. Elsevier B.V. 675 February 1, 2012, pp 84–89. https://doi.org/10.1016/j.coviro.2011.11.003. Wigginton, K. R.; Pecson, B. M.; Sigstam, T.; Bosshard, F.; Kohn, T. Virus 676 (55)677 Inactivation Mechanisms: Impact of Disinfectants on Virus Function and Structural 678 Integrity. Environ. Sci. Technol. 2012, 46 (21), 12069–12078. 679 https://doi.org/10.1021/es3029473. 680 681

SARS-CoV-2 disinfection in aqueous solution by UV₂₂₂ from a krypton chlorine excilamp **AUTHORS** Richard T. Robinson^{1,2}, Najmus Mahfooz¹, Oscar Rosas-Mejia¹, Yijing Liu³, Natalie M. Hull^{3,4*} **AFFILIATIONS** 5. Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH, USA 6. Infectious Diseases Institute, The Ohio State University, Columbus, OH, USA 7. Department of Civil, Environmental, and Geodetic Engineering, The Ohio State University, Columbus, OH, USA 8. Sustainability Institute, The Ohio State University, Columbus, OH, USA Corresponding author: Natalie Hull, hull.305@osu.edu, 2070 Neil Ave, Hitchcock 417C, Columbus, OH,43210 **CONTENTS** This supplementary information contains Figure S1 describing lamp emission and sample absorbance, Table S1 describing key parameters for UV exposures and dose

calculations, Figure S2 standard curves for qPCR and ELISA assays, and Figure S3

molecular assay concentration data for N gene or N protein at each UV dose.

682

683 684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706





Figure S1: (A) The raw spectral emission from 200 - 300 nm of the filtered excilamp (USHIO Care222®) was interpolated and relativized to the peak emission at 222 nm for use in UV dose calculations and plotted on log scale to show orders of magnitude less but non-zero emission at filtered wavelengths > 240 nm. (B) The absorbance spectrum from 200 - 300 nm of SARS-CoV-2 at ~10⁵ PFU/mL in cDMEM was measured for each of three Tests for use in UV dose calculations.


Table S1: Summary of key UV dose calculation parameters for each independent Test.

	Test 1	Test 2	Test 3
Date	1-Sep-20	16-Sep-20	4-Nov-20
UV doses (mJ/cm²)	0, 0.7, 1.1, 1.4, 1.7, 2.0, 2.7	0, 10, 16, 20, 25, 30, 40	0, 2, 4, 8, 12, 16, 20, 30
Sample exposure times (sec)	0, 29, 45, 57, 72, 87, 115	0, 214, 343, 429, 536, 643, 856	0, 84, 168, 336, 504, 672, 840, 1260
Incident irradiance at center of petri dish (mW/cm²)	1.100	2.490	1.200
Divergence factor	0.9444	0.9091	0.9091
Petri factor	0.9459	0.9147	0.9791
Water factor	0.0247	0.0232	0.0230
Average irradiance through sample depth (mW/cm²)	0.0236	0.0466	0.0238

718

719








Figure S2: N gene RT-qPCR standard curves gene copies/µL reaction for the (A) short N1 amplicon and (B) long N1-2 amplicon and (C) ELISA N protein standard curve. Colors differentiate individual assay runs.




Figure S3: N gene RT-qPCR copies/μL reaction for the (A) short N1 amplicon and (B) long N1-2 amplicon, where error bars represent standard deviation of at least two technical replicates and could include technical replicates averaged across dilutions. (C) N protein ELISA pg/mL, where error bars represent standard deviation of at least two technical replicates and could include technical replicates averaged across dilutions. Day 0 samples were analyzed immediately after UV irradiation, where Day 3 samples were analyzed in culture supernatants after incubation of samples with host cells.